false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
AAV Gene Therapy for Alport Syndrome
AAV Gene Therapy for Alport Syndrome
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Hiroyuki Nakai described AAV gene therapy research for Alport syndrome, a progressive genetic kidney disease caused by mutations in type IV collagen genes. Because COL4A5 is too large for a single AAV vector and must be delivered to podocytes, the team developed a dual-AAV strategy using protein trans-splicing to reconstitute full-length collagen.<br /><br />In mice, the approach restored COL4A5 deposition in the glomerular basement membrane and improved disease measures, but conventional AAV9 reached too few podocytes to prevent premature death. The team therefore computationally designed and screened novel capsids, identifying AAVYT1, which substantially increased podocyte transduction and collagen deposition. A liver-detargeted version retained meaningful podocyte targeting, and AAVYT1 also showed better evasion of pre-existing antibodies than available capsids.<br /><br />The researchers are preparing studies in a dog model of Alport syndrome. During discussion, Nakai noted that dual-vector treatment does not necessarily require a dramatically higher dose than single-vector treatment, though dose reduction can impair transduction. The new capsid can also reach other tissues, so podocyte-specific promoters may help limit off-target expression.
Asset Caption
Hiroyuki Nakai, MD, PhD
Meta Tag
Speaker
Hiroyuki Nakai
Keywords
Alport syndrome
AAV gene therapy
COL4A5
podocytes
dual-AAV strategy
AAVYT1 capsid
protein trans-splicing
Hiroyuki Nakai
×
Please select your language
1
English